Valuation: FamiCord AG

Market Cap 52.12M 58.39M 48.44M 44.06M 82.9M 5.53B 84.39M 582M 228M 2.89B 219M 214M 9.23B P/E 2026 *
299x
P/E 2027 * 49.8x
Enterprise Value 60.12M 67.35M 55.88M 50.83M 95.62M 6.38B 97.35M 671M 263M 3.33B 253M 247M 10.65B EV / Sales 2026 *
0.71x
EV / Sales 2027 * 0.66x
Free-Float
26.82%
Yield 2026 *
-
Yield 2027 * -
1 day-8.55%
Current month-8.55%
1 month-8.55%
3 months-8.55%
6 months-51.37%
Current year-51.37%
1 month 3.1
Extreme 3.1
3.1
Current year 3.1
Extreme 3.1
3.39
1 year 3.1
Extreme 3.1
7
3 years 3.1
Extreme 3.1
9
5 years 3.1
Extreme 3.1
9
10 years 3.1
Extreme 3.1
19.45
Manager TitleAgeSince
Chief Executive Officer 55 22/03/2022
Director of Finance/CFO 53 01/08/2024
Chief Tech/Sci/R&D Officer - 01/03/2025
Director TitleAgeSince
Chairman 62 28/06/2017
Director/Board Member - 01/01/2017
Director/Board Member 54 01/12/2021
Change 5-day change 1-year change 3-year change Capi.($)
-8.55%0.00% - - 58.39M
+2.42%+5.44%+14.76%+29.41% 118B
-0.41%+5.28%+11.48%+97.33% 101B
+2.54%+3.58%+125.61%+874.46% 58.35B
+2.45%+3.61%+27.65%+95.22% 26.4B
+2.44%+3.46%+14.97%+61.28% 26.36B
+1.30%+5.59%+38.10%+408.65% 22.15B
+0.54%-2.67%-20.50%-3.05% 20.76B
-2.17%-5.93%+5.75%+87.45% 18.53B
+0.13%+1.14%-0.62%+34.29% 17.24B
Average +0.07%+2.09%+24.13%+187.23% 45.51B
Weighted average by Cap. +1.28%+3.76%+29.00%+194.59%

Financials

2026 *2027 *
Net sales 85M 95.23M 79M 71.86M 135M 9.02B 138M 949M 371M 4.71B 357M 350M 15.06B 88.4M 99.04M 82.16M 74.73M 141M 9.38B 143M 987M 386M 4.89B 372M 364M 15.66B
Net income 300K 336K 279K 254K 477K 31.83M 486K 3.35M 1.31M 16.61M 1.26M 1.23M 53.15M 1M 1.12M 929K 845K 1.59M 106M 1.62M 11.16M 4.37M 55.36M 4.2M 4.12M 177M
Net Debt 8M 8.96M 7.44M 6.76M 12.72M 849M 12.95M 89.31M 34.95M 443M 33.63M 32.92M 1.42B 6M 6.72M 5.58M 5.07M 9.54M 637M 9.72M 66.99M 26.21M 332M 25.23M 24.69M 1.06B
Projected Income Statement - Annual - FamiCord AG
Logo FamiCord AG
FamiCord AG, formerly Vita 34 AG, is a Germany-based company operating in the medical technology sector and acts as a cell bank/stem bank. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected during the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. The cells also allow the growing of whole organs, such as the liver. On an average, one out of seven individuals, whose cells are sorted, receives autologous stem cell transplant by age of 70. The Company acts as a cord blood bank and is also engaged in research activities around regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Employees
684
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.990EUR
Average target price
6.500EUR
Spread / Average Target
+117.39%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - FamiCord AG